RBS-003 (pembrolizumab biosimilar) / Rophibio - LARVOL DELTA

Rophibio begins developing manufacturing process for Keytruda biosimilar (Korea Biomedical Review) - "Rophibio, a Korean biologics manufacturer, said Wednesday that it has entered into an agreement with Avantor, a U.S. biotech company, to supply raw materials and provide development support for a biosimilar referencing Keytruda....Rophibio, an affiliate of healthcare company Amicogen, explained that it has completed developing the biosimilar’s cell line and finished the examination of its next pipeline, adding that process development with Avantor is expected to be completed this year."

Licensing / partnership • Oncology